Pharmaceuticals News and Research

RSS

USPTO allows Pisgah Labs' patent application regarding imipramine pamoate

Pisgah Labs, a drug product development company and an active pharmaceutical ingredient manufacturer (API) located in western North Carolina, has received a patent allowance in a series of patent applications. The US Patent & Trademark Office (USPTO) has notified Pisgah Labs, Inc. that a patent application related to a therapeutically significant family of pharmaceutical polymorphic compositions of imipramine pamoate has been allowed. The patent application also includes methods of manufacturing, purifying and use in pharmaceutical preparations.

26 Mar 2010

NYU researchers identify novel therapy for rheumatoid arthritis

By enhancing the activity of immune cells that protect against runaway inflammation, researchers at NYU Langone Medical Center may have found a novel therapy for rheumatoid arthritis and other autoimmune diseases.

26 Mar 2010

Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who switched to VPRIV

Shire plc, the global specialty biopharmaceutical company, today presented positive data from a Phase III clinical trial (TKT-034) designed to evaluate the safety of switching to VPRIV (velaglucerase alfa for injection), from imiglucerase, as well as an interim analysis of safety data from an ongoing multicenter open-label treatment protocol (HGT-GCB-058) implemented to provide VPRIV to patients affected by the continuing shortage of imiglucerase.

26 Mar 2010

Researcher extracts natural scaffold for tissue growth

It frequently happens in science that what you throw away turns out to be most valuable. It happened to Deepak Nagrath, but not for long.

26 Mar 2010

Eli Lilly supports SNM's initiative to advance innovative therapies

SNM is pleased to announce that biopharmaceutical company, Eli Lilly and Company, has joined SNM's Clinical Trials Network-making it the third major company to formally support this initiative to facilitate the development of promising therapeutic medicines.

26 Mar 2010

Oramed Pharmaceuticals completes Phase 2b study of ORMD-0801 oral insulin capsule

Oramed Pharmaceuticals Inc. announced today the completion of its' pivotal Phase 2b clinical study of its oral insulin capsule, ORMD-0801. The Company expects to report results from this study within the coming weeks.

26 Mar 2010

RXi Pharmaceuticals obtains commitments to purchase 2.7M shares of common stock at $6.00 per share

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference, announced today that it has obtained commitments from several investors to purchase 2.7 million shares of its common stock at $6.00 per share and warrants to purchase 540,000 shares of its common stock for gross proceeds of $16.2 million.

26 Mar 2010

FDA grants tentative approval for Teva Pharmaceutical Industries' generic Argatroban ANDA

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market a generic version of the anticoagulant, Argatroban® injection, 100mg/mL.

26 Mar 2010

FDA approves Mirapex ER tablets for signs and symptoms of idiopathic PD

Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has approved once-daily Mirapex ER® (pramipexole dihydrochloride) extended-release tablets for the signs and symptoms of idiopathic Parkinson's disease, which includes early and advanced PD. PD is the second most common chronic neurological disorder in older adults after Alzheimer's. Parkinson's disease has no cure.

26 Mar 2010

Santarus enrolls 510 patients in Phase III clinical program for budesonide MMX

Santarus, Inc., a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX® administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. This is the second Phase III clinical study being conducted in collaboration with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals SpA, as part of the budesonide MMX Phase III clinical program for U.S. registration.

26 Mar 2010

Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has enrolled the first patient in a U.S. Phase 2 trial evaluating NOV-205 as monotherapy in up to 40 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus ribavirin.

26 Mar 2010

Hana Biosciences reports net loss of $5M for fourth quarter 2009

Hana Biosciences Inc., a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the fourth quarter and year ended December 31, 2009, and provided a corporate update.

26 Mar 2010

CorMedix announces pricing of initial public offering of 1,925,000 units at $6.50 per unit

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease, today announced the pricing of its initial public offering of 1,925,000 units at $6.50 per unit (before underwriting discounts and commissions).

26 Mar 2010

Animal study shows chymase inhibitors could advance treatments for high BP and heart failure

Millions of patients with high blood pressure and heart failure take a class of drugs known as ACE (angiotensin-converting enzyme) inhibitors. These drugs prevent the body from processing angiotensin II, a hormone that constricts blood vessels.

26 Mar 2010

JCOM receives approval from KFDA to commercialize MuGard in Korea

ACCESS PHARMACEUTICALS, INC. announced that JCOM Co., Ltd., its Korean licensee for both MuGard™ and ProLindac™, has received approval from the Korean Food and Drug Administration of its Registration Dossier for MuGard, an oncology supportive-care treatment for the management of oral mucositis.

26 Mar 2010

Malvern exhibits proven PAT solutions for real-time particle sizing at Interphex 2010

Interphex, April 20–22 New York, provides an excellent opportunity to learn how proven PAT (process analytical technology) solutions from Malvern are transforming the control of key unit operations such as milling.

25 Mar 2010

Arena Pharmaceuticals initiates patient screening for phase 1 clinical trial of APD916

Arena Pharmaceuticals, Inc. announced today the initiation of patient screening in a Phase 1 clinical trial of APD916, a novel oral drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy and cataplexy.

25 Mar 2010

Venn Life Sciences completes $3 mn funding, acquires Dutch CRO UpToYou

Venn Life Sciences has just completed a significant funding round of over $3 million, to enable it to further accelerate the growth of its business.

25 Mar 2010

Keryx Biopharmaceuticals reports net loss of $4.7M for 2009 fourth quarter

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease (the "Company"), today announced its results for the fourth quarter and year ended December 31, 2009.

25 Mar 2010

BeaconEquity.com announces investment report on AEterna Zentaris

BeaconEquity.com announces an investment report featuring AEterna Zentaris Inc. (Nasdaq:AEZS). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

25 Mar 2010

Pharmaceuticals News and Research

USPTO allows Pisgah Labs' patent application regarding imipramine pamoate

NYU researchers identify novel therapy for rheumatoid arthritis

Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who switched to VPRIV

Researcher extracts natural scaffold for tissue growth

Eli Lilly supports SNM's initiative to advance innovative therapies

Oramed Pharmaceuticals completes Phase 2b study of ORMD-0801 oral insulin capsule

RXi Pharmaceuticals obtains commitments to purchase 2.7M shares of common stock at $6.00 per share

FDA grants tentative approval for Teva Pharmaceutical Industries' generic Argatroban ANDA

FDA approves Mirapex ER tablets for signs and symptoms of idiopathic PD

Santarus enrolls 510 patients in Phase III clinical program for budesonide MMX

Novelos Therapeutics commences enrollment in Phase 2 trial of NOV-205 for chronic hepatitis C

Hana Biosciences reports net loss of $5M for fourth quarter 2009

CorMedix announces pricing of initial public offering of 1,925,000 units at $6.50 per unit

Animal study shows chymase inhibitors could advance treatments for high BP and heart failure

JCOM receives approval from KFDA to commercialize MuGard in Korea

Malvern exhibits proven PAT solutions for real-time particle sizing at Interphex 2010

Arena Pharmaceuticals initiates patient screening for phase 1 clinical trial of APD916

Venn Life Sciences completes $3 mn funding, acquires Dutch CRO UpToYou

Keryx Biopharmaceuticals reports net loss of $4.7M for 2009 fourth quarter

BeaconEquity.com announces investment report on AEterna Zentaris

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence